The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
- 
      
  
MJFF Research Grant, 2011Phenotypic Characterization of BAC LRRK2 Transgenic Pre-clinical ModelsObjective/Rationale: Mutations in the protein leucine-rich repeat kinase 2 (LRRK2) are the most common cause of inherited Parkinson’s disease (PD). Interestingly, the penetrance LRRK2 mutations and... 
- 
      
  
Rapid Response Innovation Awards, 2011Defining PARKIN Substrates Through Systematic Quantitative ProteomicsObjective/Rationale: 
 The PARK2 (Parkin) gene is frequently mutated in Parkinson’s disease. Several lines of evidence indicate that Parkin functions to catalyze the conjugation of the small protein...
- 
      
  
MJFF Research Grant, 2011Modulation of Striatal Colinergic Neuronal Activity in LIDObjective/Rationale: 
 The role of striatal cholinergic interneurons (ChIs) in Parkinson’s disease and side effects of treatment like levodopa-induced dyskinesia (LID) have been poorly studied. We have...
- 
      
  
Rapid Response Innovation Awards, 2011Intestinal Microbiota, Permeability and Alpha-synclein Aggregation in Parkinson's DiseaseObjective/Rationale: 
 Changes in the intestinal system may occur early in the development of Parkinson’s disease. The intestinal system is important to (1) maintain normal “healthy” bacteria; and (2)...
- 
      
  
Rapid Response Innovation Awards, 2011Alpha-Synuclein Knockdown: Therapeutic or Toxic?Objective/Rationale: 
 The protein alpha-synuclein (a-syn) has been conclusively linked to Parkinson’s disease. The prevailing theory today states that a-syn is a causative agent in the development of...
- 
      
  
Improving Levodopa Delivery, 2011Dry Powder-Based Delivery of Intrapulmonary Levodopa as a Treatment for Motor Fluctuations in Parkinson's DiseaseObjective/Rationale: 
 Oral levodopa pharmacokinetics are subject to excessive within- and between-subject variability, reflecting challenges inherent to gastrointestinal delivery. Aerosol delivery of...
 
  Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.